MedTrace Logo

The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

NCT06236022 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2024-02-01

No results posted yet for this study

Summary

Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.

Conditions

  • Dilated Cardiomyopathy
  • Kaposi's Sarcoma-Associated Herpesvirus Infection

Interventions

DRUG

Sirolimus

at a dose of 2 mg once daily

Sponsors & Collaborators

  • Wuhan Central Hospital

    collaborator OTHER

  • Wuhan Fourth Hospital

    collaborator UNKNOWN

  • Wuhan University

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Dao Wen Wang, Doctor · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06236022 on ClinicalTrials.gov